Physician profile
Kenny Chiu
NPI 1518073782
$15,012.87
in general payments reported to CMS, 2019-2025
44 companies · $3,321 in 2025
The $3,321 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,791 · 2020: $774 · 2021: $1,485 · 2022: $2,278 · 2023: $2,621 · 2024: $2,742 · 2025: $3,321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,439 · Education: $206 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,438.64 |
| Education | $205.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,264.75 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $2,587.03 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,099.01 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $1,018.31 | 2019-2025 | |
| Pfizer INC. | $750.95 | 2019-2025 | |
| Genzyme Corporation | $727.09 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $643.91 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $624.78 | 2021-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $468.30 | 2019-2024 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $440.44 | 2022-2023 | Zeposia |
| Ardelyx, INC. | $224.09 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $221.83 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $220.31 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $215.02 | 2024-2025 | Omvoh, Zepbound |
| Ferring Pharmaceuticals INC. | $209.10 | 2019-2022 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $200.51 | 2019-2025 | Sucraid, Sucraid |
| Mallinckrodt Hospital Products INC. | $166.63 | 2021-2025 | Terlivaz |
| Redhill Biopharma INC. | $140.86 | 2020-2023 | Talicia |
| Novo Nordisk INC | $138.14 | 2023-2025 | Wegovy |
| Daiichi Sankyo INC. | $132.07 | 2019-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $131.06 | 2019-2023 | Zinplava, Dificid |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2024 | Tezspire |
| Nestle Healthcare Nutrition INC. | $118.96 | 2021-2023 | |
| Covidien LP | $114.47 | 2019 | |
| Ethicon US, LLC | $112.63 | 2019 | |
| Ironwood Pharmaceuticals, INC | $98.40 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.62 | 2019-2024 | Cyltezo |
| Evoke Pharma, INC. | $80.27 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $70.76 | 2023-2025 | Dupixent |
| Amgen INC. | $65.28 | 2023 | Amjevita |
| Braintree Laboratories, INC. | $63.44 | 2021-2025 | Sutab, Suflave |
| Alfasigma USA, INC. | $53.71 | 2020 | |
| Aimmune Therapeutics, INC. | $52.62 | 2024-2025 | Zenpep |
| Intra-Sana Laboratories | $43.86 | 2022 | |
| Vivus LLC | $43.61 | 2019-2020 | |
| Boston Scientific Corporation | $42.22 | 2019 | |
| Romark Laboratories, Lc | $40.66 | 2020 | |
| Shionogi INC | $36.14 | 2019 | |
| Celltrion USA INC. | $33.30 | 2024-2025 | Vegzelma, Zymfentra |
| Medtronic, INC. | $31.77 | 2022 | |
| Intercept Pharmaceuticals, INC. | $26.94 | 2020 | |
| Exact Sciences Corporation | $25.96 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $15.00 | 2019 | |
| Shire North American Group INC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenny Chiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.